Algorithme secures loan to fund diversification and growth

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical research Contract research organization

CRO Algorithme Pharma has announced plans to grow and diversify its business after securing support of Canadian financiers.

The support is in the form of a loan from Investissement Quebec (IQ) and investment from existing company shareholders and will be key to expanding Algorithime’s early-stage research business according to CEO Chris Perkin.


[This loan] will allow the Company to implement the strategies needed to position itself as a leading early stage clinical contract research organization.


Perkin went on to say that this plan involves adding new capabilities, entering new geographical and research markets, but did not go into specifics.


At present Algorithme has two clinical research facilities in Canada in Montreal and Laval and a foothold in Europe and an office in Japan though its sister organisation, Merthyr Tydfil, Wales-headquartered Simbec Research.


Alan Woodward, business development manager at Simbec, reiterated that the new financing will be used to fund expansion, telling this will include increasing Phase I first-in-human capacity with the addition of a new laboratory at Algorithme’s Montreal site.


[The additional funds] will also be used to invest in new software such as an electronic data capture (EDC) and Document management system and additional staff from increased business development to scientists and managers​.”


On the acquisition trail

 Woodward also spoke about Algorithime’s wider expansion plans, explaining that the contract research organisations (CRO) is “actively pursuing alliances that will extend our capabilities or global reach and in the next 18 months or so we anticipate an acquisition in either US or Europe​.”

Algorithme’s last acquisition spree in August 2008​ saw it acquire both Simbec and a clinical research centre in Baltimore, Maryland in the US.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more